التفاصيل البيبلوغرافية
| العنوان: |
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. |
| المؤلفون: |
Nghiemphu, Phioanh, Dombi, Eva, Nguyen, Thien, Wagle, Naveed, Ishiyama, Akira, Sepahdari, Ali, Cachia, David, Widemann, Brigitte, Brackmann, Derald, Doherty, Joni, Kalamarides, Michel, Giovannini, Marco, Vitte, Jeremie |
| المصدر: |
Journal of Neuro-Oncology, vol 167, iss 2 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2024 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Clinical trial, Everolimus, Mammalian target of rapamycin (mTOR) inhibitors, NF2, Quantitative imaging biomarkers, Vestibular schwannoma, Humans, Neuroma, Acoustic, Quality of Life, Treatment Outcome, Neurofibromatosis 2, Biomarkers |
| الوصف: |
PURPOSE: NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas (VS) often causing hearing and neurologic deficits, with currently no FDA-approved drug treatment. Pre-clinical studies highlighted the potential of mTORC1 inhibition in delaying schwannoma progression. We conducted a prospective open-label, phase II study of everolimus for progressive VS in NF2 patients and investigated imaging as a potential biomarker predicting effects on growth trajectory. METHODS: The trial enrolled 12 NF2 patients with progressive VS. Participants received oral everolimus daily for 52 weeks. Brain imaging was obtained quarterly. As primary endpoint, radiographic response (RR) was defined as ≥ 20% decrease in target VS volume. Secondary endpoints included other tumors RR, hearing outcomes, drug safety and quality of life (QOL). RESULTS: Eight participants completed the trial and four discontinued the drug early due to significant volumetric VS progression. After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%. There was no VS RR and 3 of 8 (37.5%) participants had stable disease. Decreased or unchanged VS volume after 3 months of treatment was predictive of stabilization at 12 months. Seven of eight participants had stable hearing during treatment except one with a decline in word recognition score. Ten of twelve participants reported only minimal changes to their QOL scores. CONCLUSIONS: Volumetric imaging at 3 months can serve as an early biomarker to predict long-term sensitivity to everolimus treatment. Everolimus may represent a safe treatment option to decrease the growth of NF2-related VS in patients who have stable hearing and neurological condition. TRN: NCT01345136 (April 29, 2011). |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt1hj7m14d; https://escholarship.org/uc/item/1hj7m14dTest |
| الإتاحة: |
https://escholarship.org/uc/item/1hj7m14dTest |
| حقوق: |
public |
| رقم الانضمام: |
edsbas.74B689E7 |
| قاعدة البيانات: |
BASE |
